ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

olokizumab

Also written as “CDP6038”, “Olokizumab” and “OKZ q4w”.

Its studies are mostly in Arthritis, Rheumatoid · COVID-19 · Polymyalgia Rheumatica · Arthritis, Juvenile · Lung Diseases, Interstitial, led by 2 companies.

Drug pageOlokizumab: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 29, 201619 company-led studies, 3 open or runningNext primary completion: Apr 9, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
R-Pharm113 open or runningphase 3since Apr 29, 2016Apr 29, 2016Apr 9, 2027phase 3 · NCT06440746
UCBits history only80 open or runningphase 2since Nov 4, 2009Nov 4, 2009none ahead

Also a collaborator on its studies: Keystat, Exacte Labs, Data Management 365, IQVIA Pvt., Quintiles, K-Research, Cromos Pharma and Covance.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of R-Pharm only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 29, 2016First studies: 3 phase 3 studies in Arthritis, RheumatoidFirst studyNCT02760433, NCT02760407, NCT02760368
  2. Feb 7, 2017Phase 3 study in Arthritis, RheumatoidNCT03120949 · 2,106 enrolled · United States, Argentina, Belarus and more
  3. Jan 27, 2020Phase 1 study in Arthritis, RheumatoidNCT04246762 · 17 enrolled · Bulgaria, Moldova, Republic of
  4. May 6, 2020Phase 3 study in COVID-19NCT04380519 · 372 enrolled · Russian Federation
  5. Jun 25, 2020Phase 3 study in COVID-19NCT04452474
  6. Dec 24, 2021Phase 3 study in COVID-19NCT05187793 · 198 enrolled · Russian Federation
  7. May 28, 2024Phase 3 study in Lung Diseases, InterstitialNCT06440746 · 138 planned · Russian Federation
  8. Dec 30, 2025Phase 2 study in Arthritis, JuvenileNCT07517575 · 71 planned · Russia
  9. Jun 19, 2026Phase 3 study in Polymyalgia RheumaticaNCT07670546 · 125 enrolled · Russia

Ahead

  1. Apr 9, 2027Primary completion: phase 3 study in Lung Diseases, InterstitialNCT06440746

TargetBeta

IL6 →read by rule
“A humanized monoclonal antibody directed against the pro-inflammatory cytokine interleukin-6 (IL-6), ”NCIt, by rule
“Interleukin-6 inhibitor”ChEMBL 37, by rule

Other programs on IL6

ProgramCompanyFurthest phaseStudies
ziltivekimabruleNovo Nordiskphase 312
clazakizumabCSLphase 310
pacibekitugruleNovartisphase 31
isomyosamineruletnf-pharmaceuticals-incphase 21

Studies

All 11 R-Pharm leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07670546Polymyalgia Rheumatica · Russia3Active, not recruitingApr 10, 2026125
NCT07517575Arthritis, Juvenile · Russia2RecruitingSep 202671
NCT06440746Lung Diseases, Interstitial · Russian Federation3RecruitingApr 9, 2027138
NCT05187793COVID-19 · Russian Federation3UNKNOWNOct 31, 2022198
NCT04452474COVID-193WithdrawnNov 16, 20200
NCT04380519COVID-19 · Russian Federation3CompletedJul 10, 2020372
NCT04246762Arthritis, Rheumatoid · Bulgaria, Moldova, Republic of1CompletedJun 8, 202217
NCT03120949Arthritis, Rheumatoid · United States, Argentina, Belarus and more3CompletedSep 1, 20212,106
NCT02760433Arthritis, Rheumatoid · United States, Argentina, Brazil and more3CompletedSep 12, 2019368
NCT02760407Arthritis, Rheumatoid · United States, Argentina, Brazil and more3CompletedAug 2, 20191,648
NCT02760368Arthritis, Rheumatoid · Belarus, Bulgaria, Russian Federation3CompletedAug 2018428

How it is read

Names in the registry

  • “CDP6038”, 13 entries
  • “Olokizumab”, 5 entries
  • “OKZ q4w”, 2 entries
  • “CDP6038 (olokizumab)”, 2 entries
  • “Olokizumab 64 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.